AstraZeneca Outlines Growth Ambitions – Could This Include Oncology Leadership By 2030?
Not content with fulfilling its decade-long $45bn sales target, AstraZeneca is now preparing for Act 2: a new 10-year 'cycle of growth'.
You may also be interested in...
When AstraZeneca closed out big pharma earnings season, its usually dominant therapeutic franchise missed analysts’ expectations. Merck’s, on the other hand, did not disappoint.
The company licensed an oral GLP-1 agonist from Eccogene, hoping to capitalize on its heritage in cardiovascular disease. AstraZeneca also reported third quarter results.
Data from a histological subgroup have come to the rescue for AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd along with reassurance over its safety profile in advanced NSCLC, while overall survival data are still awaited.